Latest Bevacizumab Stories
There may be new found hope for patients whose vision is threatened when medicine injected directly into the eyes fails to cause abnormal blood vessels to recede.
This week, the second-year results of an important clinical trial on age-related macular degeneration (AMD), known as the Comparison of AMD Treatments Trials (or CATT), were published in the journal Ophthalmology.
Two drugs commonly used to treat age-related macular degeneration (AMD) yield similar improvements in vision for patients receiving treatments on a monthly or as-needed basis.
At two years, Avastin (bevacizumab) and Lucentis (ranibizumab injection), two widely used drugs to treat age-related macular degeneration (AMD), improve vision when administered monthly or on an as needed basis, although greater improvements in vision were seen with monthly administration for this common, debilitating eye disease.
Tokyo, Apr 23, 2012 - (JCN Newswire) - Eisai Co., Ltd.
On Tuesday, April 17, researchers from the University of California, San Francisco (UCSF) presented results at the American Association of Neurological Surgeons (AANS) meeting in Miami, Florida that a new brain cancer vaccine tailored to individual subjects had been successful in its second clinical trial.
Adding the drug bevacizumab (Avastin) to the standard chemotherapy regimen for non-small cell lung cancer (NSCLC) – an approach approved by the FDA in 2006 – did not lead to significantly increase survival rates for patients over the age of 65 enrolled in Medicare, a new study by Dana-Farber Cancer Institute researchers has found.
- A coin originally worth six pennies Scots, and later three; held equivalent to an English halfpenny.
- (in plural) Money; cash.